Literature DB >> 27150803

Trans-Splenic Portal Vein Embolization: A Technique to Avoid Damage to the Future Liver Remnant.

Ammar Sarwar1, Olga R Brook2, Jeffrey L Weinstein2, Khalid Khwaja3, Muneeb Ahmed2.   

Abstract

Portal vein embolization (PVE) induces hypertrophy of the future liver remnant (FLR) in patients undergoing extensive hepatic resection. Portal vein access for PVE via the ipsilateral hepatic lobe (designated for resection) places veins targeted for embolization at acute angles to the access site requiring reverse curve catheters for access. This approach also involves access close to tumors in the ipsilateral lobe and requires care to avoid traversing tumor. Alternatively, a contralateral approach (through the FLR) risks damage to the FLR due to iatrogenic trauma or non-target embolization. Two patients successfully underwent PVE via trans-splenic portal vein access, allowing easy access to the ipsilateral portal veins and eliminating risk of damage to FLR. Technique and advantages of trans-splenic portal vein access to perform PVE are described.

Entities:  

Keywords:  Oncology; Portal vein embolization; Trans-splenic access

Mesh:

Year:  2016        PMID: 27150803     DOI: 10.1007/s00270-016-1359-5

Source DB:  PubMed          Journal:  Cardiovasc Intervent Radiol        ISSN: 0174-1551            Impact factor:   2.740


  3 in total

1.  Portal vein embolization for induction of selective hepatic hypertrophy prior to major hepatectomy: rationale, techniques, outcomes and future directions.

Authors:  David Li; David C Madoff
Journal:  Cancer Biol Med       Date:  2016-12       Impact factor: 4.248

2.  The transjugular approach is a safe and effective alternative for performing portal vein embolization.

Authors:  Ming-Shan Jiang; Xue-Feng Luo; Zhu Wang; Xiao Li
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

3.  Feasibility and Safety of Delayed Catheter Removal Technique in Percutaneous Trans-Hepatic Portal Vein Embolization.

Authors:  Chengjian He; Naijian Ge; Yefa Yang
Journal:  Technol Cancer Res Treat       Date:  2022 Jan-Dec
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.